病例344:肝脏上皮质形血管内皮质瘤
Lasya Daggumati1, Lauren Stark2, Adam L Booth2
1University of Missouri Kansas City School of Medicine, Kansas City, Mo.
Radiology
|January 27, 2026
概括
一位健康的女性经历了持续的胃肠道症状. 进行了成像研究,包括CT和MRI,以调查她不适的原因.
科学领域:
- 胃肠病学 胃肠病学
- 放射学 放射学是一门学科.
背景情况:
- 一个以前健康的33岁妇女出现了几个月的间歇性右上象限不适,早期的和,胀气和恶心.
- 她过去没有明显的病史,包括没有已知的恶性瘤,慢性肝病或药物滥用.
研究的目的:
- 在以前健康的女性中调查持续性胃肠道症状的原因.
- 用先进的成像技术评估肝脏发现.
主要方法:
- 腹部和骨盆CT与静脉注射对比.
- 腹部MRI带有和没有静脉注射对比剂.
- 进行了实验室研究,包括肝功能面板和血清瘤标志物.
主要成果:
- 身体检查和实验室研究,包括肝功能面板和血清瘤标记物 (α-fetoprotein,癌胚抗原,癌症抗原19-9),都在正常范围内.
- 腹部和骨盆的CT显示没有肝外病理特征.
- 腹部的MRI进行了进一步评估肝脏发现.
结论:
- 认为需要对肝脏发现进行进一步评估.
- 患者的胃肠道症状的原因需要进一步调查,尽管最初的治疗正常.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
269
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
269
Hepatic Portal System
5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
224
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
224
Hepatic Drug Excretion: Influencing Factors
562
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
562
Hepatic Drug Clearance: Role of Transporters
306
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
306
Hepatic Drug Excretion: Enterohepatic Cycling
2.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.7K


